3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
4
Completed
4
Active not recruiting
2
Withdrawn
1
Recruiting
1
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Colorectal Neoplasms
4
Venous Thromboembolism
2
Thrombocythemia, Essential
1
Testicular Neoplasms
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Ovarian Neoplasms
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Hemorrhage
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Breast Neoplasms
1
Interventions
Blood Specimen Collection
38
pembrolizumab
36
Bevacizumab
22
Surveys and Questionnaires
18
Standard of Care
18
Radiotherapy
18
Exercise
17
Carboplatin
16
Nivolumab
15
atezolizumab
14
Cisplatin
14
Drug Therapy
13
Paclitaxel
12
Fluorouracil
12
Cyclophosphamide
12
Cetuximab
12
Trastuzumab
10
Leucovorin
10
Docetaxel
10
Dexamethasone
10
Pemetrexed
9
Oxaliplatin
9
Biopsy
9
pertuzumab
8
olaparib
8
Temozolomide
8
Panitumumab
8
Observation
8
Irinotecan
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms
×
Aspirin
×
Clear all
NCT06866964
2026-02-02
ASPIRE
Wake Forest University Health Sciences
Phase 2
Recruiting
35 enrolled